LY2886721

SKU: orb1301111

Description

LY2886721 is a potent and selective BACE1 inhibitor developed for Alzheimer's disease research. It has been utilized in both in vitro enzymatic assays and in vivo preclinical models to investigate the inhibition of amyloid-beta peptide production and its potential therapeutic effects.

Research Area

Neuroscience

Key Properties

• CAS Number: 1262036-50-9
• MW: 390.41
• Purity: 99.94% (May vary between batches)
• Formula: C₁₈H₁₆F₂N₄O₂S
• SMILES: NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F
• Target: Beta-Secretase,BACE
• Solubility: DMSO:1 mg/mL (2.56 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  BACE1:20.3 nM|BACE2:10.2 nM
• In Vitro:
  LY2886721 is an oral, small molecule of β-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the Clinicalal progression of AD. LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

sAPPβ, βSecretase, β-Secretase, Alzheimer's, BBB, Beta-secretase, BetaSecretase, b-Secretase, bSecretase, C99, BACE, BACE1, BACE2, disease, Inhibitor, inhibit, LY2886721, LY-2886721, LY 2886721

Compound Identifiers

PubChem CID

49837968